arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

BioAge Labs, Inc.

BIOA

$11.75 ▲ +0.53 (+4.72%) at close

14 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Moderately Bearish

auto_awesome

Analytical Summary

BioAge Labs, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $499.1M

Dividend Yield —

Revenue Growth 91.0%

Op. Margin —

ROIC -5.3% ↗

FCF / Share $-0.57

Trailing P/E —

Price / Book 1.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.77M

↑ +91.0% —

Net Income Profit after all expenses

$-22.25M

↓ -72.1% —

FCF / Share Free cash flow per share

$-0.57

↓ -14.2% —

Long-Term Debt Long-term obligations

$0.00

— —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health →

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	91.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1038%)	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	-44.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	91.6% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	92.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	95.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	23.3% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-72.1% Weak ↓ Weak Declining Year-over-year change in net income	-22.8% Weak ↓ Weak Declining Year-over-year change in net income	0.5% Caution ↑ Caution Improving Year-over-year change in net income	0.5% Caution ↑ Caution Improving Year-over-year change in net income	0.5% Caution ↑ Caution Improving Year-over-year change in net income	-0.8% Weak Weak Year-over-year change in net income	-17.2% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	-14.2% Weak Weak Year-over-year change in free cash flow	—	—	93.9% Excellent Excellent Year-over-year change in free cash flow	94.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	1.08x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.24x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.56x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.38x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.24x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.22x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.21x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-5.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-8.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.1% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	5.5% Caution ↓ Caution Declining Return earned on debt + equity capital invested Optimal: > 10%	6.5% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	5.1% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-6.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-7.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-7.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-52.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-5.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-139%)	-9.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-164%)	-4.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-4.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-129%)	-4.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	-6.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-144%)	-4.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	6.6% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-56%)	7.0% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-53%)	12.1% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-19%)	7.2% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-52%)	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	—	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.00x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	0.02x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-96%)	0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	0.03x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-95%)	—	—	-0.05x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-108%)	—	—	—	—
Interest Coverage (x)	-618.90x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-334.39x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-173.98x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-140.74x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-75.79x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-92.23x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-39.87x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-30.01x Weak Weak Operating income divided by interest expense Optimal: > 5x	-29.05x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-241.78M	$-188.89M	$-215.57M	$-220.33M	$-250.43M	$-351.85M	$-324.53M	—	$-173.99M	$-13.44M	—	—	—	—
Debt / EBITDA (x)	—	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.43x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.10x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.40x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	-0.61x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.07	—	$0.06	$0.07	$0.04	—	—	$0.00	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.52	$-0.72	$-0.56	$-0.60	$-0.36	$15.13	$-6.70	$-7.94	$-7.76	$-12.53	$-8.74	—	—	—
Free Cash Flow per Share (USD)	$-0.57	—	$-0.45	$-0.56	$-0.50	—	—	$-9.24	$-9.36	—	—	—	—	—
Book Value per Share (USD)	$8.54	$7.28	$7.74	$8.22	$8.74	$9.01	$9.17	$-115.21	$-110.85	$-103.62	$-91.55	—	—	—
Tangible Book Value per Share (USD)	$8.54	$7.28	$7.74	$8.22	$8.74	$9.01	$9.17	$-115.21	$-110.85	$-103.62	$-91.55	—	—	—
Basic Weighted Avg Shares (shares)	42.48M	—	35.85M	35.85M	35.85M	—	3.49M	1.71M	1.67M	—	1.67M	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$376.03M	$266.65M	$266.33M	$278.86M	$301.07M	$329.33M	$317.39M	—	—	$-32.86M	—	—	—	—
LT Debt (USD)	—	$0.00	$0.00	$0.00	$7.06M	$2.50M	$9.94M	—	—	$8.20M	—	—	—	—
Total Equity (USD)	$379.12M	$272.05M	$277.46M	$294.78M	$313.17M	$323.13M	$313.75M	$-197.13M	$-185.51M	$-173.40M	$-153.14M	$-139.31M	$-122.92M	$-112.56M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$2.77M	$3.08M	$2.05M	$2.41M	$1.45M	$0.00	—	$0.00	—	—	—	—	—	—
Depreciation Expense (USD)	—	—	—	—	—	$100.00K	—	—	—	$100.00K	—	—	—	—
Net Income, GAAP (USD)	$-22.25M	$-25.94M	$-12.93M	$-12.93M	$-12.93M	$-21.13M	$-12.99M	$-12.99M	$-12.99M	$-20.96M	$-11.08M	—	—	—
Operating Cash Flow (USD)	$-24.05M	$-28.25M	$-16.04M	$-19.97M	$-17.36M	$-5.14M	—	$-15.78M	$-15.67M	$-8.50M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

BioAge Labs, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BIOA with peers